Craniospinal irradiation in the treatment of chemotherapy refractory leptomeningeal metastasis from breast cancer: A case report.
breast cancer
craniospinal irradiation
leptomeningeal metastasis
Journal
Cancer reports (Hoboken, N.J.)
ISSN: 2573-8348
Titre abrégé: Cancer Rep (Hoboken)
Pays: United States
ID NLM: 101747728
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
revised:
11
08
2021
received:
08
06
2021
accepted:
01
09
2021
pubmed:
12
11
2021
medline:
29
7
2022
entrez:
11
11
2021
Statut:
ppublish
Résumé
Leptomeningeal carcinomatosis is a relatively uncommon complication of solid tumors that is associated with significant morbidity and mortality. Prognosis is typically weeks to months and the neurologic complications of this disease can significantly affect quality of life. The role of craniospinal irradiation is unclear as evidence exploring this treatment option is limited. Despite lack of evidence, its use has decreased due to its associated acute toxicities and newer intrathecal alternatives. Here we report the case of a 50-year-old patient who received craniospinal irradiation for chemotherapy-refractory leptomeningeal disease, with survival well beyond the median and good quality of life for the majority of that time. This patient's remarkable survival and performance after treatment suggests that craniospinal irradiation could be considered more frequently in the treatment of leptomeningeal metastases. To our knowledge, this is the first case with significant survival following craniospinal irradiation for chemotherapy refractory disease presented. Further study on the use of craniospinal irradiation to treat leptomeningeal metastasis is recommended.
Sections du résumé
BACKGROUND
Leptomeningeal carcinomatosis is a relatively uncommon complication of solid tumors that is associated with significant morbidity and mortality. Prognosis is typically weeks to months and the neurologic complications of this disease can significantly affect quality of life. The role of craniospinal irradiation is unclear as evidence exploring this treatment option is limited. Despite lack of evidence, its use has decreased due to its associated acute toxicities and newer intrathecal alternatives.
CASE
Here we report the case of a 50-year-old patient who received craniospinal irradiation for chemotherapy-refractory leptomeningeal disease, with survival well beyond the median and good quality of life for the majority of that time.
CONCLUSION
This patient's remarkable survival and performance after treatment suggests that craniospinal irradiation could be considered more frequently in the treatment of leptomeningeal metastases. To our knowledge, this is the first case with significant survival following craniospinal irradiation for chemotherapy refractory disease presented. Further study on the use of craniospinal irradiation to treat leptomeningeal metastasis is recommended.
Identifiants
pubmed: 34761557
doi: 10.1002/cnr2.1556
pmc: PMC9327655
doi:
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1556Informations de copyright
© 2021 The Authors. Cancer Reports published by Wiley Periodicals LLC.
Références
Nat Rev Clin Oncol. 2014 Apr;11(4):203-22
pubmed: 24569448
J Thorac Oncol. 2015 Jan;10(1):156-63
pubmed: 25247337
Hematol Oncol Stem Cell Ther. 2019 Dec;12(4):189-193
pubmed: 31629723
J Neurooncol. 2018 May;138(1):191-198
pubmed: 29435818
Ann Oncol. 2017 Jul 1;28(suppl_4):iv84-iv99
pubmed: 28881917
Curr Opin Oncol. 2010 Nov;22(6):627-35
pubmed: 20689429
Clin Breast Cancer. 2015 Feb;15(1):66-72
pubmed: 25287959
Med Oncol. 2013 Mar;30(1):408
pubmed: 23322521
Clin Neurol Neurosurg. 2018 Sep;172:151-159
pubmed: 30015053
Indian J Cancer. 2014 Oct-Dec;51(4):410-3
pubmed: 26842139
Arch Neurol. 1997 Jan;54(1):16-7
pubmed: 9006407
Neuro Oncol. 2021 Jan 30;23(1):134-143
pubmed: 32592583
Cancer Rep (Hoboken). 2022 Jul;5(7):e1556
pubmed: 34761557
Cancer. 1982 Feb 15;49(4):759-72
pubmed: 6895713
Cancer Chemother Pharmacol. 2013 Jul;72(1):201-7
pubmed: 23670641
BMC Cancer. 2020 Jun 1;20(1):501
pubmed: 32487151
Neuro Oncol. 2020 Apr 15;22(4):524-538
pubmed: 31637444
Med Oncol. 2000 Aug;17(3):151-62
pubmed: 10962524
Cancer Manag Res. 2018 Dec 31;11:401-409
pubmed: 30643465
Cancer. 2010 Apr 15;116(8):1947-52
pubmed: 20151421
Cancer Manag Res. 2019 Jan 17;11:789-801
pubmed: 30697071
Strahlenther Onkol. 2001 Apr;177(4):195-9
pubmed: 11370554
J Neurooncol. 2007 Aug;84(1):57-62
pubmed: 17310266
Cancer Chemother Pharmacol. 2012 Sep;70(3):399-405
pubmed: 22806307
Neurol Sci. 2015 Sep;36(9):1691-3
pubmed: 25990104
Front Oncol. 2019 Nov 15;9:1224
pubmed: 31803614
J Neurooncol. 2013 May;113(1):83-92
pubmed: 23456656
Cancer Treat Res. 2005;125:31-52
pubmed: 16211882
Cancer Treat Rep. 1977 Jul;61(4):733-43
pubmed: 577896
Mol Clin Oncol. 2014 Jan;2(1):116-120
pubmed: 24649318
ESMO Open. 2019 May 21;4(Suppl 2):e000507
pubmed: 31231573